Britain and America have forged a key trade agreement that will guarantee zero tariffs on UK drug exports entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise funding on pharmaceuticals through the public health system. This move guarantees that tariffs on these crucial goods will stay at nothing for a timeframe of 36 months.
This agreement comes after previous warnings to dramatically increase tariffs on patented pharmaceutical products, with figures floated up to double the cost.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and introduces long-overdue balance to transatlantic medicine commerce," a release said.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's biggest export categories to the America, which is clearly the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value accounted for 17.4% of all goods exports in that period.
"This agreement secures jobs, stimulates funding and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several specific commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. In the past, repayments were more than 20%.
Recent Tensions
The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were intensified by arguments that US consumers were charged significantly more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward American operations.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
